Document is current

Any future updates will be listed below

Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer

Crossref DOI link: https://doi.org/10.1186/s12967-022-03453-0

Published Online: 2022-06-27

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark